Aggressive joint pharmacokinetic/pharmacodynamic target attainment of TDM-guided continuous infusion meropenem-vaborbactam monotherapy: A valuable strategy for maximizing the microbiological outcome of documented KPC-producing Enterobacterales infect

OBJECTIVE: To assess whether attaining an aggressive joint pharmacokinetic/pharmacodynamic (PK/PD) target of therapeutic drug monitoring (TDM)-guided continuous infusion (CI) meropenem-vaborbactam monotherapy may be a valuable strategy for maximizing the microbiological outcome of documented KPC-producing Enterobacterales infections. METHODS: ) ratio >24. Multivariate analysis was performed for assessing potential independent predictors of microbiological failure. RESULTS: Overall, 55 patients were included. Aggressive joint PK/PD target of meropenem-vaborbactam was attained in 96.3% (53/55) of cases. Among 44/55 patients having follow-up cultures (80.0%), 9 experienced microbiological failure (20.5%), and 2 developed 90-day resistance (4.5%). Continuous renal replacement therapy (OR, 15.00; 95% CI: 1.75-128.40; P = 0.013) and intrabdominal infection (OR, 10.00; 95% CI: 1.36-73.33; P = 0.024) emerged as independent predictors of microbiological failure. Aggressive joint PK/PD target was non-attained more frequently among patients having microbiological failure than in those having microbiological eradication (22.2% vs. 0.0%; P = 0.038), although not statistically significant at multivariate analysis. CONCLUSIONS: Our findings suggest that a TDM-guided monotherapy of documented KPC-producing Enterobacterales infections focused on aggressive joint PK/PD target attainment with CI meropenem-vaborbactam could represent a valuable strategy either for granting microbiological cure and for counteracting resistance development.